Back to News
Market Impact: 0.2
Creative Medical Expands Ultrasome Intellectual Property Portfolio
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & BiotechTechnology & Innovation
Creative Medical Technology Holdings filed a new U.S. provisional patent application to broaden intellectual-property protection for its proprietary Ultrasome regenerative-medicine platform. The filing could strengthen CELZ's technology moat and development optionality, but the article provides no clinical, commercial, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CELZ0.55
More News
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Blackstone president calls for more equity to fund AI buildout as debt risks mount
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70